GLP-1semaglutideliraglutidetirzepatidepediatric obesity

Review weighs GLP-1 and GIP/GLP-1 agonists in pediatric obesity

Randomized trials show BMI reduction with liraglutide and semaglutide, but no randomized tirzepatide trial exists in children without diabetes.

By Maren Holt · Senior Reporter, GLP-1

Sep 14 20:00 ETSource: International journal of molecular sciences

The wire

01A narrative review in IJMS synthesizes pediatric trial data, reporting the largest mean BMI effect with semaglutide in adolescents.
02Clinicians treating adolescents get a consolidated read on growth, puberty and bone-health uncertainties alongside implementation guidance.
03Long-term effects on growth, body composition and weight maintenance remain undefined, and the authors call for integration with behavioral and family-based care.

From the source

GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application
International journal of molecular sciences · 2026 Sep 15 · Myśliwczyk D, Myśliwiec M, Minarowska A et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42794619/